4th annual Rare & Genetic Kidney Disease Drug Development Summit
Uncover Disease Pathophysiology, Clarify Response Biomarkers, Leverage Electronic Health Records & Implement Patient-Centric Recruitment Strategies to Accelerate Game-Changing Therapies to Patients
With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.
Returning to Boston this December, the 4th annual Rare & Genetic Kidney Disease Drug Development Summit will unite 30+ experts speakers including Novartis, FDA, XORTX Therapeutics, Walden Biosciences, and more to discuss the acceleration of clinical advancements in orphan kidney disease populations.
What’s new for 2024?
- A 2-streamed pre-conference workshop day diving into topics including pinpointing molecular mechanisms underlying podocytopathies, as well as pricing, reimbursement, market access and value communication to insurers, payers and prescribers
- Join interactive discussions delving into molecular intricacies and fundamental mechanisms of rare kidney disease in preclinical models to identify potential future therapies
- Connect with your peers as you explore evolving strategies for rare renal patient subgroup identification using electronic health records
- Hear from a world-class line-up of speakers at the forefront of the industry as they dive into validating biomarkers of drug response and disease progression, baking endpoints and patient-centric outcome measures into clinical trial design, and much more
Download the agenda here: https://ter.li/ri2wch
Register early to make the most of the early bird savings available – as well as up to 20% off if you bring your colleagues! Register online here: https://ter.li/9onizs
Dates: December 10-12 2024
Location: Revere Hotel Boston, 200 Stuart St, MA 02116, United States
Event Program: https://ter.li/ri2wch
